Search

Your search keyword '"S. Manier"' showing total 16 results
Start Over Author "S. Manier" Database Directory of Open Access Journals
16 results on '"S. Manier"'

1. B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL

Author

P. Rodríguez-Otero, S. Ailawadhi, B. Arnulf, K. Patel, M. Cavo, A.K. Nooka, S. Manier, N. Callander, L.J. Costa, R. Vij, N.J. Bahlis, P. Moreau, S.R. Solomon, M. Delforge, J. Berdeja, A. Truppel-Hartmann, Z. Yang, L. Favre-Kontula, F. Wu, J. Piasecki, M. Cook, and S. Giralt

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

3. S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL

Author

C. Hasselbalch Riley, M. Hutchings, S.-S. Yoon, Y. Koh, S. Manier, T. Facon, S. J. Harrison, J. Er, F. Volzone, A. Pinto, C. Montes, E. M. Ocio, A. Alfonso-Pierola, P. Rodriguez Otero, F. Offner, A. Guidetti, P. Corradini, C. Titouan, C. Hulin, C. Touzeau, P. Moreau, R. Popat, S. Leong, R. Mazza, A.-M. E. Bröske, I. Dekhtiarenko, H.-J. Helms, S. Belli, T. Vardar, T. Fauti, J. Eckmann, T. Moore, M. Schneider, W. Jacob, M. Weisser, and C. Carlo-Stella

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

4. S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS

Author

C. Touzeau, A. Krishnan, P. Moreau, A. Perrot, S. Z. Usmani, S. Manier, M. Cavo, C. Martinez-Chamorro, A. Nooka, T. Martin, L. Karlin, X. Leleu, N. Bahlis, B. Besemer, L. Pei, R. Verona, S. Girgis, C. Uhlar, R. Kobos, and A. Garfall

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

5. S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

I. Dekhtiarenko, I. Lelios, J. Attig, N. Sleiman, D. Lazzaro, I. Clausen, N. Gräfe, H.-J. Helms, E. Schindler, S. Belli, T. Fauti, J. Eckmann, P. Umana, W. Jacob, M. Schneider, C. Hasselbalch Riley, M. Hutchings, S.-S. Yoon, Y Koh, S. Manier, T. Facon, S. J. Harrison, J. Er, F. Volzone, A. Pinto, C. Montes, E. M. Ocio, A. Alfonso-Pierola, P. Rodríguez Otero, F. Offner, A. Guidetti, P. Corradini, C. Titouan, C. Hulin, C. Touzeau, P. Moreau, R. Popat, S. Leong, R. Mazza, C. Carlo-Stella, and A.-M. E. Bröske

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

6. P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01

Author

A. Bobin, S. Manier, J. De Keizer, L. Karlin, A. Perrot, C. Hulin, D. Caillot, C. Mariette, P. Lenain, V. Richez, M. Tiab, C. Touzeau, A. Jaccard, O. Decaux, C. Araujo, K. Belhadj, L. Benboubker, C. Déal, M. Macro, L. Vincent, B. Arnulf, B. Bareau, T. Braun, C. Calmettes, D. mamoun, H. Zerazhi, H. Demarquette, P. Feugier, C. Fohrer-sonntag, S. Godet, M.-O. Petillon, H. Avet-Loiseau, and X. Leleu

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

8. P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE

Author

A. Schavgoulidze, A. Perrot, T. Cazaubiel, X. Leleu, S. Manier, L. Buisson, S. Maheo, L. Do Souto Ferreira, R. Lannes, L. Pavageau, C. Hulin, J.-P. Marolleau, L. Voillat, K. Belhadj, M. Divoux, B. Slama, S. Brechignac, M. Macro, A.-M. Stoppa, L. Sanhes, F. Orsini-Piocelle, J. Fontan, M.-L. Chretien, H. Demarquette, M. Mohty, H. Avet-Loiseau, and J. Corre

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

10. P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).

Author

M. Macro, C. Touzeau, C. Mariette, S. Manier, S. Brechignac, L. Vincent, B. Hebraud, O. Decaux, S. Schulmann, C. Lenoir, P. Godmer, A. Farge, L. Peyro Saint Paul, J.-J. Parienti, and X. Leleu

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

11. P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO-HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT

Author

R. Tilmont, I. Yakoub-Agha, D.-J. Eikema, N. Zinger, M. Haenel, N. Schaap, C. Herrera Arroyo, C. Schuermans, W. Bethge, M. Engelhardt, J. Kuball, M. Michieli, N. Schub, K. M. O. Wilson, J. H. Bourhis, M. V. Mateos, N. Robin, E. Jost, N. Kröger, J. M. Moraleda, S. Sica, P. J. Hayden, M. Beksac, S. Schönland, and S. Manier

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

12. P1257: MOLECULAR CHARACTERIZATION AND CLONAL EVOLUTION OF MYCOSIS FUNGOIDES

Author

L. Fléchon, I. Arib, A. Dutta, R. Sklanvenitis Pistofidis, C. Stewart, R. Dubois, S. Poulain, M.-C. Copin, S. Javed, M. Nudel, L. Hasan Bou Issa, A. Ouelkite-Oumouchal, S. Faiz, O. Carpentier, L. Mortier, S. Mitra, M. Figeac, F. Morschhauser, B. Quesnel, I. Ghobrial, and S. Manier

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

13. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma

Author

S. Manier, J. Park, M. Capelletti, M. Bustoros, S. S. Freeman, G. Ha, J. Rhoades, C. J. Liu, D. Huynh, S. C. Reed, G. Gydush, K. Z. Salem, D. Rotem, C. Freymond, A. Yosef, A. Perilla-Glen, L. Garderet, E. M. Van Allen, S. Kumar, J. C. Love, G. Getz, V. A. Adalsteinsson, and I. M. Ghobrial

Subjects
Science
Abstract

Circulating tumor cells (CTCs) and cell-free DNA (cfDNA) enables characterization of a patient’s cancer. Here, the authors analyse CTCs, cfDNA, and tumor biopsies from multiple myeloma patients to show these approaches are complementary for mutation detection, together enabling a greater fraction of patient tumors to be profiled.

Published
2018
Full Text
View/download PDF

14. EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN–DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES

Author

A Nooka, A Lesokhin, M Mohty, R Niesvizky, C Maisel, B Arnulf, S Larson, A Varshavsky-Yanovsky, X Leleu, L Karlin, D Vesole, N Bahlis, CF Larrea, N Raje, E Leip, U Conte, M Elmeliegy, A Viqueira, V Blunk, and S Manier

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Introduction/Objectives: To evaluate the efficacy and safety of elranatamab in a pooled analysis of patients (pts) enrolled in MagnetisMM trials with relapsed or refractory multiple myeloma (RRMM) who had prior exposure to B-cell maturation antigen (BCMA)-directed therapy. Materials and methods: Eligible pts received at least 1 proteasome inhibitor, 1 immunomodulatory drug, 1 anti-CD38 antibody, and 1 BCMA-directed therapy (antibody-drug conjugate [ADC] and/or chimeric antigen receptor [CAR]-T cells). The pooled analysis included pts in the MagnetisMM-1 trial (NCT03269136; n = 13) who received subcutaneous (SC) elranatamab 215-1000 μg/kg; MM-3 (NCT04649359; n = 64) and MM-9 (NCT05014412; n = 9) who received the recommended phase 2 dose of 76 mg SC once-weekly. Efficacy endpoints were evaluated by investigator per IMWG criteria. TEAEs were graded by CTCAE (MM-1, v4.03; MM-3 & MM-9, v5.0); CRS and ICANS were graded by ASTCT criteria. Results include data up through ≍10 months after last pt initial dose in all pooled studies. Results: In total, 86 pts were included. Median age was 66.0 y (range, 40-84); 47.7% male. At baseline, 69.8% had an ECOG PS ≥1; 24.4% had high risk cytogenetics; 54.7% had extramedullary disease. Pts received a median of 7.0 (3-19) prior lines of therapy, including BCMA-directed ADC (67.4%), CAR T-cells (41.9%); 9.3% received both. 96.5% and 54.7% of pts were triple-class and penta-drug refractory, respectively; among pts who received ADC and CAR-T cells respectively, 79.3% and 27.8% were refractory to ADC and CAR-T cells. After a median follow-up of 10.3 mo (0.3-32.3), median duration of treatment was 3.3 mo (0.03-30.4). At the cut-off date, 24.4% of pts remained on treatment; most common reason for permanent treatment discontinuation was progressive disease (44.2%). The overall response rate (ORR) was 45.3% (95% CI 34.6-56.5), with ≥CR achieved in 17.4% of pts. ORR for pts with prior BCMA-directed ADC and CAR-T cells was 41.4% (95% CI 28.6-55.1) and 52.8% (95% CI 35.5-69.6), respectively. Among responders, median time to objective response was 1.9 mo (0.3-9.3). Median duration of response (DOR) was not reached by 10 mo; the DOR rate at 9 mo was 72.4% (95% CI 54.7-84.2). DOR rate (95% CI) for pts with prior BCMA-directed ADC and CAR-T cells were 67.3% (43.1-83.0) and 78.9% (53.2-91.5) at 9 mo, respectively. Median progression-free survival was 4.8 mo (95% CI 1.9-7.7); median overall survival was not reached by 10 mo, with a rate of 60.1% (95% CI 48.9-69.6) at 9 mo. Most common (≥25% of pts) TEAEs were CRS (65.1% [G3 1.2%]), anemia (59.3% [G3/4, 46.5%]), neutropenia (44.2% [G3/4, 40.7%]), thrombocytopenia (40.7% [G3/4, 29.1%]), diarrhea (33.7% [G3/4, 0%], and lymphopenia (32.6% [G3/4, 30.2%]). 5.8% (G3, 2.3%) of pts. Discussion: In pts with RRMM and prior exposure to BCMA-directed therapies, elranatamab was efficacious and well tolerated; no new safety signals were observed vs the BCMA-naïve population. Conclusions: These results support treatment with elranatamab in pts with RRMM post BCMA-directed therapy.

Published
2023
Full Text
View/download PDF

15. EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3

Author

N Raje, X Leleu, A Lesokhin, M Mohty, A Nooka, E Leip, U Conte, A Viqueira, V Blunk, and S Manier

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Introduction/Objectives: Multiple myeloma is a disease of elderly and frail people, who are often predominantly ineligible for intensive therapies. The objective of this analysis is to report the efficacy and safety of elranatamab monotherapy by age and frailty in B-cell maturation antigen-naïve patients (pts) with relapsed or refractory multiple myeloma (RRMM) enrolled into cohort A of the ongoing phase 2 MagnetisMM -3 (NCT04649359) study. Materials and methods: Eligibility criteria, dosing and administration were previously reported (Bahlis et al, ASH 2022). Subgroups of pts within Cohort A (n = 123) were analyzed by age:

Published
2023
Full Text
View/download PDF

16. P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

Author

R Popat, A Badros, S Kumar, P Rodriguez-Otero, A Cohen, S Manier, P Voorhees, F Gay, R Rifkin, T Martin, A Chari, K Weisel, A Farooq, B Jeng, W Chng, H Lee, J Berdeja, V Jadhav, A Tosolini, L Eliason, A Palumbo, M Dimopoulos, S Lonial, S Trudel, P Richardson, and E Terpos

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results